Unique ID issued by UMIN | UMIN000009565 |
---|---|
Receipt number | R000010482 |
Scientific Title | Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer. |
Date of disclosure of the study information | 2012/12/17 |
Last modified on | 2012/12/17 14:43:42 |
Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer.
KGCSG1201
Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer.
KGCSG1201
Japan |
HER2-positive Stage IV advanced gastric cancer
Gastrointestinal surgery |
Malignancy
NO
Evaluation of the efficacy and safety of S-1/Paclitaxel/Trastuzumab combination chemotherapy as 1st line therapy on HER2-positive Stage IV advanced gastric cancer.
Safety
Exploratory
Pragmatic
Phase II
Safety
Overall survival,Progression-free-survival,Response Rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
S-1/Paclitaxel/Trastuzumab combination chemotherapy
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically proven advanced gastric cancer.
2) Positive HER2 status(IHC3+ or IHC2+/FISH+)
3) Age of 20 years or older.
4) Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
5) Without previous medication history for advanced gastric cancer.
6) Patient who has more than one measurable or evaluable lesion.
7) Patient who is possible of ingestion.
8) Adequate organ function.
*WBC count 3,500-12,000/mm3
*Neutrophils count more than 2,000/mm3
*Platelet count more than 100,000/mm3.
*Hemoglobin more than 8.0 g/dl.
*Total bilirubin level less than 1.5 mg/dl
*AST and ALT less than 100 IU/l
*Creatinine clearance more than 60mL/min
9) LVEF more than 50% within 28 days.
10) Electrocardiogram was performed within 28 days.
11) Life expectancy of at least 3 months after registration.
12) Written informed conscent to receive this chemotherapy.
1)Forbidden case to use S-1, Paclitaxel and Trastuzumab.
2)Patient who want to be pregnant and /or pregnant woman. Intend to make pregnant.
3)Infection or inflammatory case.
4)Active hepatitis type HBs positive.
5)Severe heart disease.
6)Severe complicated case.
7)Watery diarrhea.
8)Bleeding from tumor or ulceration.
9)Multiple bone metastasis.
10)Clinical suspicion or previous history of metastasis to brain or meninges.
11)Complicated other active cancer.
12)Operated within 28 days.
13)Mental disability requiring medical treatment.
14)Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study.
20
1st name | |
Middle name | |
Last name | Syoji Natsugoe |
Graduate School of Medical Science Kagoshima University
Department of Digestive Surgery, Breast and Thyroid Surgery
8-35-1 Sakuragaoka, kagoshima city, kagoshima
1st name | |
Middle name | |
Last name | Sumiya Ishigami |
Graduate School of Medical Sciences Kagoshima University
Department of Digestive Surgery, Breast and Thyroid Surgery
8-35-1 Sakuragaoka, kagoshima city, kagoshima
Department of Digestive Surgery, Breast and Thyroid Surgery
Graduate School of Medical Science
Kagoshima University
none
Self funding
NO
2012 | Year | 12 | Month | 17 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 11 | Month | 17 | Day |
2012 | Year | 01 | Month | 01 | Day |
2012 | Year | 12 | Month | 17 | Day |
2012 | Year | 12 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010482